12:00 AM
 | 
May 14, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

AeroVanc: Phase Ia data

Top-line data from 18 healthy volunteers in the Phase Ia portion of an open-label, vancomycin-controlled, Australian Phase Ia/Ib trial showed that single doses of 16, 32 and 80 mg AeroVanc were...

Read the full 135 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >